Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
NCT04462965
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
294
Enrollment
OTHER
Sponsor class
Conditions
Mucosal Melanoma
Interventions
COMBINATION_PRODUCT:
Toripalimab
COMBINATION_PRODUCT:
Temozolomide
Sponsor
Peking University Cancer Hospital & Institute